[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1986

Treatment of Cytomegalovirus Retinopathy in Patients With Acquired Immunodeficiency SyndromeUse of the Experimental Drug 9-[2-Hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine

Author Affiliations

From the AIDS Unit of the UCLA Uveitis Center, the Jules Stein Eye Institute (Drs Holland, Sakamoto, Sidikaro, and Kreiger), and the Departments of Ophthalmology (Drs Holland, Sakamoto, Sidikaro, and Kreiger), Medicine (Dr Hardy), and Pediatrics (Dr Frenkel), UCLA School of Medicine. The names of additional participants appear at the end of this article.

Arch Ophthalmol. 1986;104(12):1794-1800. doi:10.1001/archopht.1986.01050240068042
Abstract

• Cytomegalovirus (CMV) retinopathy, a relentlessly progressive disease that results in permanent blindness, is the most common opportunistic infection of the eye in patients with the acquired immunodeficiency syndrome. Twenty patients with the acquired immunodeficiency syndrome with CMV retinopathy were treated with a new, experimental, antiviral drug, 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (BW B759U), in dosages ranging from 5.0 to 14.0 mg/kg/d for a ten- to 20-day course. In 19 patients (95%), treatment halted the progression of infection and decreased retinal opacification, hemorrhage, and vasculitis. Vision remained stable in most cases. Six patients received no additional treatment. Fourteen patients received continued treatment with a lower maintenance dosage. Retinal disease reactivated in all patients who did not receive maintenance therapy immediately after initial treatment, indicating persistence of live virus despite drug therapy. Reactivation of disease also developed in four (40%) of ten patients receiving continuous, uninterrupted maintenance therapy for longer than three weeks. Reversible neutropenia, requiring cessation of treatment, developed in five (25%) of 20 patients on initial treatment and five (36%) of 14 patients receiving maintenance therapy. Rhegmatogenous retinal detachment was a late complication in four patients. BW B759U appears to be useful in the management of CMV retinopathy by reducing or delaying visual loss.

References
1.
Holland GN, Pepose JS, Pettit TH, et al:  Acquired immune deficiency syndrome: Ocular manifestations . Ophthalmology 1983;90:859-872.Article
2.
Pepose JS, Holland GN, Nestor MS, et al:  Acquired immunodeficiency syndrome: Pathogenic mechanisms of ocular disease . Ophthalmology 1985;92:472-484.Article
3.
Palestine AG, Rodriques MM, Macher AM, et al:  Ophthalmic involvement in acquired immune deficiency syndrome . Ophthalmology 1984;91:1092-1099.Article
4.
Newsome DA, Green WR, Miller ED, et al:  Microvascular aspects of acquired immune deficiency syndrome retinopathy . Am J Ophthalmol 1984;98:590-601.
5.
Egbert PR, Pollard RB, Gallagher JG, et al:  Cytomegalovirus retinitis in immunosuppressed hosts: II. Ocular manifestations . Ann Intern Med 1980;93:664-670.Article
6.
Pollard RB, Egbert PR, Gallagher JG, et al:  Cytomegalovirus retinitis in immunosuppressed hosts: I. Natural history and effects of treatment with adenine arabinoside . Ann Intern Med 1980; 93:655-664.Article
7.
Chou S, Dylewski JS, Gaynon MW, et al:  Alpha-interferon administration in cytomegalovirus retinitis . Antimicrob Agents Chemother 1984;25:25-28.Article
8.
Mar E-C, Cheng Y-C, Huang E-S:  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro . Antimicrob Agents Chemother 1983;24:518-521.Article
9.
Cheng Y-C, Huang E-S, Lin J-C, et al:  Unique spectrum of activity of 9-[(1,3-dihydroxy2-propoxy)methyl]guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1 . Proc Natl Acad Sci USA 1983;80:2767-2770.Article
10.
Tocci MJ, Liuelli TJ, Perry HC, et al:  The effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication . Antimicrob Agents Chemother 1984;25:247-252.Article
11.
Felsenstein D, D'Amico DJ, Hirsch MS, et al:  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine . Ann Intern Med 1985;103:377-380.Article
12.
Shepp DH, Dandliker PS, de Miranda P, et al:  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia . Ann Intern Med 1985;103:368-373.Article
13.
Bach MC, Bagwell SP, Knapp NP, et al:  9-(1,3-dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome . Ann Intern Med 1985;103:381-382.Article
14.
Palestine AG, Stevens G, Lane HC, et al:  Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine . Am J Ophthalmol 1986;101:95-101.
15.
Masur H, Lane HC, Palestine A, et al:  Effect of 9-[1,3-dihydroxy-2-propoxymethyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men . Ann Intern Med 1986;104:41-44.Article
16.
Collaborative DHPG Treatment Study Group:  Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies . N Engl J Med 1986;314:801-805.Article
17.
Rosecan LR, Stahl-Bayliss CM, Kalman CM, et al:  Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine . Am J Ophthalmol 1986;101:405-418.
18.
 Centers for Disease Control: Update on acquired immune deficiency syndrome (AIDS)— United States . MWWR 1982;31:507-508, 513-514.
19.
 Centers for Disease Control: Revision of case definition of acquired immunodeficiency syndrome for national reporting—United States . MWWR 1985;34:373-374.
20.
Meredith TA, Aaberg TM, Reeser FH:  Rhegmatogenous retinal detachment complicating cytomegalovirus retinitis . Am J Ophthalmol 1979;87:793-796.
21.
Macher AM, Reichert CM, Straus SE, et al:  Death in the AIDS patient: Role of cytomegalovirus . N Engl J Med 1983;309:1454-1462.
×